| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 201 |
| 1 | LETROZOLE | 171 |
| 2 | BEVACIZUMAB | 159 |
| 3 | OXALIPLATIN | 155 |
| 4 | RIBOCICLIB | 150 |
| 5 | FULVESTRANT | 134 |
| 6 | LETROZOLE TABLETS | 130 |
| 7 | FLUOROURACIL | 123 |
| 8 | FLUOROURACIL CREAM, 0.5% | 123 |
| 9 | REGORAFENIB | 101 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DACOMITINIB | 26 | 0.0347 |
| 1 | PENICILLAMINE | 10 | 0.0108 |
| 2 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 3 | 0.0098 |
| 3 | REGORAFENIB | 101 | 0.0087 |
| 4 | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE | 8 | 0.0071 |
| 5 | PANITUMUMAB | 100 | 0.0062 |
| 6 | DATOPOTAMAB DERUXTECAN | 5 | 0.0058 |
| 7 | VANDETANIB | 9 | 0.0050 |
| 8 | TRIFLURIDINE AND TIPIRACIL | 50 | 0.0046 |
| 9 | ZOLBETUXIMAB | 7 | 0.0046 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 362 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 354 |
| 2 | Platinum-based Drug [EPC] | 240 |
| 3 | Aromatase Inhibitor [EPC] | 220 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 171 |
| 5 | Epidermal Growth Factor Receptor Antagonist [EPC] | 150 |
| 6 | Estrogen Receptor Antagonist [EPC] | 141 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 103 |
| 8 | RANK Ligand Inhibitor [EPC] | 91 |
| 9 | Corticosteroid [EPC] | 89 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 7 | 0.0046 |
| 1 | Estrogen Receptor Antagonist [EPC] | 141 | 0.0035 |
| 2 | Epidermal Growth Factor Receptor Antagonist [EPC] | 150 | 0.0032 |
| 3 | Provitamin D2 Compound [EPC] | 61 | 0.0021 |
| 4 | Aromatase Inhibitor [EPC] | 220 | 0.0019 |
| 5 | Endoglycosidase [EPC] | 3 | 0.0016 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 10 | 0.0016 |
| 7 | Blood Viscosity Reducer [EPC] | 6 | 0.0014 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 354 | 0.0013 |
| 9 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 103 | 0.0010 |